Formulary Chapter 2: Cardiovascular system - Full Chapter
|
Chapter Links... |
NICE CG107: Hypertension in pregnancy: diagnosis and management |
NICE CG108: Chronic heart failure in adults: management |
NICE CG126: Stable angina: management |
NICE CG127: Hypertension in adults: diagnosis and management |
NICE CG180: Atrial fibrillation: management |
NICE CG68: Stroke and transient ischaemic attack in over 16s: diagnosis and initial management |
NICE NG185; Acute coronary syndromes |
Details... |
02.05 |
Drugs affecting the renin-angiotensin system and some other antihypertensive drugs |
|
|
Ambrisentan
|
Formulary
|
|
|
Macitentan (Opsumit®)
|
Formulary
|
NHS England commissioned
|
|
Metirosine
|
Formulary
|
|
|
Milrinone (Primacor®)
|
Formulary
|
|
|
02.05.01 |
Vasodilator antihypertensive drugs |
|
|
Hydralazine (tablets)
|
Formulary
|
|
|
Minoxidil (Loniten®) (Tablets)
|
Formulary
|
Use on specialist advice only
|
|
Bosentan
|
Formulary
|
|
|
Iloprost (Injection)
|
Formulary
|
|
|
Iloprost nebules (Vantavis®)
|
Formulary
|
NHS England commissioned
|
|
Sildenafil
|
Formulary
|
|
|
Sodium nitroprusside
|
Formulary
|
Injection (Secondary Care only)
|
|
02.05.02 |
Centrally acting antihypertensive drugs |
|
|
Clonidine Hydrochloride (Catapres®) (tablets)
|
Formulary
|
Use only on advice of specialist
|
|
Clonidine Liqiud
|
Formulary
|
|
|
Methyldopa (Tablets)
|
Formulary
|
|
|
Moxonidine (Tablets)
|
Formulary
|
|
|
02.05.03 |
Adrenergic neurone blocking drugs |
|
|
02.05.04 |
Alpha-adrenoceptor blocking drugs |
|
|
Doxazosin
|
Formulary
|
|
Patient Information: Changes to doxazosin prescribing
|
02.05.04 |
Phaeochromocytoma |
|
|
Phenoxybenzamine
|
Formulary
|
|
|
02.05.05 |
Drugs affecting the renin-angiotensin system |
|
|
|
|
02.05.05 |
Heart Failure |
|
|
Sacubitril valsartan (Entresto®) (film coated tablets)
|
Formulary
|
Use current status at Place/Trust
Sandwell
Supported by RICaD
Sacubatril valsartan(Entresto) RICaD -Sandwell only
Wolverhampton
Walsall
Dudley
Entresto-Implementation of Entresto (Sacubitril/Valsartan) in Dudley Health Economy
|
NICE TA388:Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction
|
02.05.05.01 |
Angiotensin-converting enzyme inhibitors (ACE inhibitors) |
|
|
Perindopril erbumine (Tablets)
|
Formulary
|
DO NOT PRESCRIBE as perindopril arginine salt-Perindopril arginine is Black on the formulary
|
|
Ramipril (Capsules, Tablets)
|
Formulary
|
Prescribe as capsules
|
|
Lisinopril
|
Formulary
|
|
|
Captopril (tablets)
|
Formulary
|
For existing patients and Paediatric use
|
|
|
02.05.05.02 |
Angiotensin-II receptor antagonists |
|
|
Candesartan cilexetil (Tablets)
|
Formulary
|
|
|
Irbesartan (Tablets)
|
Formulary
|
|
|
Losartan (Tablets)
|
Formulary
|
|
|
Valsartan (Capsules)
|
Formulary
|
|
|
02.05.05.03 |
Renin inhibitors |
|
|
Aliskiren (Rasilez®) (Tablets)
|
Formulary
|
Guidance for CCGs: Items which should not be routinely prescribed in primary care
|
|
.... |
Non Formulary Items |
Atenolol with nifedipine
|
Non Formulary
|
|
|
Azilsartan
|
Non Formulary
|
|
|
Captopril and Hydrochlorothiazide (Capozide®)
|
Non Formulary
|
|
|
Captopril and Hydrochlorothiazide (Co-zidocapt®)
|
Non Formulary
|
|
|
Cilazapril (Vascace®)
|
Non Formulary
|
|
|
Co-flumactone
|
Non Formulary
|
|
|
Co-tenidone (atenolol and chlortalidone)
|
Non Formulary
|
|
|
Cozaar- Comp®
|
Non Formulary
|
|
|
Enalapril (tablets)
|
Non Formulary
|
For existing patients only |
|
Enalapril Meleate and Hydrochlorothiazide (Innozide®)
|
Non Formulary
|
|
|
Ephedrine
|
Non Formulary
|
|
|
Eprosartan (Teveten®)
|
Non Formulary
|
|
|
Fosinopril Sodium
|
Non Formulary
|
|
|
Guanethidine Monosulphate
|
Non Formulary
|
|
|
Hydralazine Hydrochloride (Apresoline®)
|
Non Formulary
|
|
|
Hydrochlorothiazide
|
Non Formulary
|
|
|
Imidapril Hydrochloride (Tanatril®)
|
Non Formulary
|
|
|
Indoramin (Baratol®)
|
Non Formulary
|
|
|
Indoramin (Doralese®)
|
Non Formulary
|
|
|
Irbesartan with hydrochlorothiazide
|
Non Formulary
|
|
|
Lisinopril (Zestril®)
|
Non Formulary
|
|
|
Lisinopril and Hydrochlorothiazide (Carace® Plus, Lisicostad®, Zestoretic®)
|
Non Formulary
|
|
|
Losartan with hydrochlorothiazide
|
Non Formulary
|
|
|
Moexipril Hydrochloride (Perdix®)
|
Non Formulary
|
|
|
Olmesartan (Sevikar®)
|
Non Formulary
|
|
|
Olmesartan with amlodipine
|
Non Formulary
|
|
|
Olmesartan with amlodipine and hydrochlorothiazide
|
Non Formulary
|
|
|
Olmesartan with hydrochlorothiazide
|
Non Formulary
|
|
|
Perindopril
|
Non Formulary
|
|
|
Perindopril Arginine (Coversyl® Arginine) (Tablets)
|
Non Formulary
|
In line with NHS England's Guidance for CCGs: Items which should not routinely be prescribed in primary care (Dec 2017)
Click here to access guidance |
Patient Information: Changes to perindopril arginine prescribing
|
Perindopril arginine with indapamide
|
Non Formulary
|
|
|
Phentolamine
|
Non Formulary
|
|
|
Prazosin
|
Non Formulary
|
|
|
Prazosin (Hypovase®)
|
Non Formulary
|
|
|
Quinapril
|
Non Formulary
|
|
|
Quinapril and Hydrochlorothiazide
|
Non Formulary
|
|
|
Ramipril and Felodipine (Triapin®)
|
Non Formulary
|
|
|
Rasitro®
|
Non Formulary
|
|
|
Sevikar HCT®
|
Non Formulary
|
|
|
Sitaxentan Sodium (Thelin®)
|
Non Formulary
|
|
|
Tadalafil
|
Non Formulary
|
Non formulary for:
- Lower urinary tract symptoms in benign prostatic hyperplasi |
|
Tadalafil (Adcirca®)
|
Non Formulary
|
|
|
Telmisartan
|
Non Formulary
|
|
|
Telmisartan with hydrochlorothiazide
|
Non Formulary
|
|
|
Terazosin
|
Non Formulary
|
|
|
Terazosin (Hytin®)
|
Non Formulary
|
|
|
Timolol with amiloride and hydrochlorothiazide
|
Non Formulary
|
|
|
Timolol with bendroflumethiazide
|
Non Formulary
|
|
|
Tolazoline
|
Non Formulary
|
|
|
Trandolapril (Gopten®)
|
Non Formulary
|
|
|
Trandolapril and Verapamil (Tarka®)
|
Non Formulary
|
|
|
Treprostinil
|
Non Formulary
|
|
|
Triamterene with chlortalidone
|
Non Formulary
|
|
|
Valsartan with hydrochlorothiazide
|
Non Formulary
|
|
|
|
Key |
|
Restricted Drug |
|
Unlicensed |
|
Link to adult BNF
|
|
Link to children's BNF
|
|
Link to SPCs
|
|
Cytotoxic Drug |
|
Controlled Drug |
|
|
High Cost Medicine |
|
Cancer Drugs Fund |
|
NHS England |
|
Homecare |
|
ICB |
|
Low carbon footprint |
|
Medium carbon footprint |
|
High carbon footprint |
|
Status |
Description |
|
Medicines which are suitable for initiation and maintenance prescribing by primary and secondary care clinicians. These medicines should be initiated and prescribed within their licensed indications |
|
Amber Specialist Initiation: Initiation and maintenance of prescribing by Specialists and transfer to Primary Care prescribing when appropriate. This may be supported by a RICaD, annotated within the formulary entry. |
|
Amber Shared Care: Initiation and maintenance of prescribing by Specialists and transfer to Primary Care prescribing, in accordance with an ESCA, annotated within the formulary entry. |
|
Amber Specialist Recommendation: Initiation and maintenance of prescribing in Primary Care following recommendation from a specialist. |
|
Medicines for initiation and maintenance prescribing by Specialists (hospital or GPs with Special Interest) only |
|
Positive NICE TA and /or awaiting local clarification on place in therapy; Please contact your Medicines Optimisation team for more information. |
|
Non-formulary Medicines which APC/Trust DTC has actively reviewed and do not recommend for use. |
|
Check Notes as varies across the area |
|
|
|